ino-5151
Vaccineexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03835533)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03835533 | Phase 1 | Jun 30, 2019 | Bristol-Myers Squibb, Cancer Research Institute, Celldex Therapeutics, Inovio Pharmaceuticals, Oncovir, Inc., The Parker Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Celldex Therapeutics | For profit | 1 | 0 | 1 | 2019 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2019 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2019 |
| The Parker Institute | Academic/Hospital | 1 | 1 | 1 | 2019 |
6 organizations
Page 1 / 1